KALV — Kalvista Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Kalvista Pharmaceuticals Announces Pricing Of $55 Million Underwritten Offering Of Common Stock
Brief: Kalvista Appoints Brian Piekos As Chief Financial Officer
Kalvista Pharmaceuticals Inc reports results for the quarter ended in July 31 - Earnings Summary
Brief: Kalvista Pharmaceuticals Q1 Net Income USD -40.443 Million
Kalvista Pharmaceuticals Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
Brief: KalVista Announces Validation Of Marketing Authorization Application By The European Medicines Agency
U.S. RESEARCH ROUNDUP: Boston Beer Company, Inter Parfums, Netflix
Brief: Kalvista Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Kalvista Pharmaceuticals Inc reports results for the quarter ended in April - Earnings Summary
Brief: Kalvista Pharmaceuticals Says Potential FDA Approval And Launch Of Sebetralstat In First Half of 2025
Brief: Kalvista Pharmaceuticals Q4 Net Income USD -44.65 Million
Kalvista Pharmaceuticals Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Kalvista Initiates Konfident-Kid Trial For On-Demand Treatment
Brief: KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
Brief: KalVista Pharmaceuticals Highlights Strategic Plans For Coming Fiscal Year
Kalvista Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary
Brief: Kalvista Pharmaceuticals Q3 Net Income USD -29.028 Million
Brief: Adage Capital Partners GP Reports 6.87% Passive Stake In Kalvista Pharmaceuticals As Of Feb 15